Hematology Times
|
|
LymphomasVaccine effective in B-cell lymphoma
DLBCL cells
Researchers have shown that vaccination with the Toll-like receptor 9 agonist stimulates systemic antilymphoma responses in patients with low-grade B-cell lymphoma by inducing tumor-reactive CD8 T cells. What’s more, the vaccine is not a customized product, but a clinically practical, off-the-shelf vaccine. Senior author Ronald Levy, MD, of Stanford University Medical Center in California, and colleagues reported the findings August 30 online ahead of print in the Journal of Clinical Oncology. ... [Read Article] Low vitamin D linked to inferior EFS/OS in NHL
A retrospective study of newly diagnosed non-Hodgkin’s lymphoma (NHL) patients found a link between insufficient levels of vitamin D and inferior event-free survival (EFS) and overall survival (OS) among patients with some types of NHL. The team, led by James R. Cerhan, MD PhD, of the Mayo Clinic in Rochester, followed 983 patients for a median of 34.8 months after measuring their 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels. The study was published online ahead of print August 16 in the Journal of Clinical Oncology. ... [Read Article] Study highlights benefits of bortezomib and biomarkers
Mantle cell lymphoma cells
A recent study in the July issue of Leukemia & Lymphoma describes how bortezomib works in mantle cell lymphoma, as well as ways researchers could use biomarkers to speed up clinical trials and the development of targeted cancer drugs. This study is the first to look at biomarkers in lymphoma using bortezomib. Andre Goy, MD, believes clinical trials can be better designed in the future so that phase 2 research can answer some questions currently addressed in phase 3 trials. ... [Read Article] RIT with DLI increases long-term survival in FL
Follicular lymphoma cells
A recent study published in the Journal of Clinical Oncology found that treating follicular lymphoma (FL) patients who underwent transplantation using fludarabine, melphalan, and alemtuzumab for in vivo T-cell depletion may result in a more widely tolerable treatment or cure. Currently, the majority of FL patients cannot tolerate allogeneic transplantation due to excessive toxicity, hence the search for reduced-intensity conditioning regimens. ... [Read Article] HBV linked to non-Hodgkin’s lymphoma
DLBCL cells
A recent study published online in The Lancet Oncology suggests that patients who are positive for hepatitis B surface antigen (HBsAg) may be at an increased risk of developing non-Hodgkin’s lymphoma (NHL). Researchers followed 603,585 participants from the Korean Cancer Prevention Study for up to 14 years. Of the 53,045 participants who were HBsAg positive at baseline, 133 developed NHL. Among participants who were HBsAg negative at baseline, 905 developed NHL. ... [Read Article] |
|